The Latin America, Middle East and Africa Clinical Trial Supply & Logistics Market would witness market growth of 13.6% CAGR during the forecast period (2022-2028).
Numerous clinical drug supply groups have difficulty keeping up with advances such as gene and cell therapy and decentralized trials. These developments necessitate the development of new supply capabilities, such as viral-vector manufacturing, patient-device management, and in-home services, which clinical drug supply functions cannot produce independently, efficiently, or rapidly.
Instead of turning inward, leaders in clinical drug supply are creating external collaborations with contract research organizations (CROs), technology suppliers, and other strategic partners. The pharmaceutical supply chain is undergoing a monumental change due to a more complicated regulatory environment; mounting pressure to boost operational efficiency and streamline costs by modernizing traditionally burdensome and error-prone processes; and the rise of personalized medicines, which require close supply chain collaboration and patient-centric orchestration.
To remain competitive, pharma supply chain organizations must integrate technologies and rely on product serialization to assure inventory visibility from beginning to end. However, the time, complexity, and resources required to create point-to-point interfaces with trading partners are prohibitively expensive. To ensure success in this environment, an enabling technology, a broad digital network of trading partners in the cloud that eliminates barriers to integration and enables businesses to arrange their supply chains around the patient's individual needs, is required.
The Argentine Ministry of Health (ANMAT) adopted a new law on April 26 that drastically decreases the clearance process for clinical studies. The new rule will reduce the evaluation period from 160 business days to no more than 70 days. The president of Argentina expects the number of trials being conducted in the country to treble in the next two years now that the updated legislation is in place. The Argentinean Chamber of Pharmaceutical Products said that 20 studies had been approved in the past two weeks, indicating that this new law already has a significant influence. Thus, government activities surrounding clinical trials enable sponsors to concentrate on conducting trials and developing further treatments. Consequently, these factors are driving the demand for the LAMEA Clinical Trial Supply & Logistics Market.
The Brazil market dominated the LAMEA Clinical Trial Supply & Logistics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $126 Million by 2028.The Argentina market is exhibiting a CAGR of 14.2% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 13.3% during (2022 - 2028).
Based on End-user, the market is segmented into Pharmaceuticals, Biologicals and Medical Device. Based on Therapeutic Area, the market is segmented into Cardiovascular Diseases, Respiratory Diseases, CNS & Mental Disorders, Oncology and Others. Based on Phase, the market is segmented into Phase III, Phase II, Phase I and Phase IV. Based on Service, the market is segmented into Logistics & Distribution, Comparator Sourcing, Storage & Retention, Packaging, Labeling, & Blinding, Manufacturing and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Catalent, Inc., Marken (United Parcel Service of America, Inc.), Piramal Enterprises Limited, FedEx Corporation, Inizio Group Limited (Clayton, Dubilier & Rice), Parexel International Corporation (Phoenix Parentco, Inc.), Almac Group, Movianto (Walden Group SAS), and Deutsche Post DHL Group (The Deutsche Post AG)
Numerous clinical drug supply groups have difficulty keeping up with advances such as gene and cell therapy and decentralized trials. These developments necessitate the development of new supply capabilities, such as viral-vector manufacturing, patient-device management, and in-home services, which clinical drug supply functions cannot produce independently, efficiently, or rapidly.
Instead of turning inward, leaders in clinical drug supply are creating external collaborations with contract research organizations (CROs), technology suppliers, and other strategic partners. The pharmaceutical supply chain is undergoing a monumental change due to a more complicated regulatory environment; mounting pressure to boost operational efficiency and streamline costs by modernizing traditionally burdensome and error-prone processes; and the rise of personalized medicines, which require close supply chain collaboration and patient-centric orchestration.
To remain competitive, pharma supply chain organizations must integrate technologies and rely on product serialization to assure inventory visibility from beginning to end. However, the time, complexity, and resources required to create point-to-point interfaces with trading partners are prohibitively expensive. To ensure success in this environment, an enabling technology, a broad digital network of trading partners in the cloud that eliminates barriers to integration and enables businesses to arrange their supply chains around the patient's individual needs, is required.
The Argentine Ministry of Health (ANMAT) adopted a new law on April 26 that drastically decreases the clearance process for clinical studies. The new rule will reduce the evaluation period from 160 business days to no more than 70 days. The president of Argentina expects the number of trials being conducted in the country to treble in the next two years now that the updated legislation is in place. The Argentinean Chamber of Pharmaceutical Products said that 20 studies had been approved in the past two weeks, indicating that this new law already has a significant influence. Thus, government activities surrounding clinical trials enable sponsors to concentrate on conducting trials and developing further treatments. Consequently, these factors are driving the demand for the LAMEA Clinical Trial Supply & Logistics Market.
The Brazil market dominated the LAMEA Clinical Trial Supply & Logistics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $126 Million by 2028.The Argentina market is exhibiting a CAGR of 14.2% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 13.3% during (2022 - 2028).
Based on End-user, the market is segmented into Pharmaceuticals, Biologicals and Medical Device. Based on Therapeutic Area, the market is segmented into Cardiovascular Diseases, Respiratory Diseases, CNS & Mental Disorders, Oncology and Others. Based on Phase, the market is segmented into Phase III, Phase II, Phase I and Phase IV. Based on Service, the market is segmented into Logistics & Distribution, Comparator Sourcing, Storage & Retention, Packaging, Labeling, & Blinding, Manufacturing and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Catalent, Inc., Marken (United Parcel Service of America, Inc.), Piramal Enterprises Limited, FedEx Corporation, Inizio Group Limited (Clayton, Dubilier & Rice), Parexel International Corporation (Phoenix Parentco, Inc.), Almac Group, Movianto (Walden Group SAS), and Deutsche Post DHL Group (The Deutsche Post AG)
Scope of the Study
Market Segments Covered in the Report:
By End-user
- Pharmaceuticals
- Biologicals
- Medical Device
By Therapeutic Area
- Cardiovascular Diseases
- Respiratory Diseases
- CNS & Mental Disorders
- Oncology
- Others
By Phase
- Phase III
- Phase II
- Phase I
- Phase IV
By Service
- Logistics & Distribution
- Comparator Sourcing
- Storage & Retention
- Packaging, Labeling, & Blinding
- Manufacturing
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Catalent, Inc
- Marken (United Parcel Service of America, Inc.)
- Piramal Enterprises Limited
- FedEx Corporation
- Inizio Group Limited (Clayton, Dubilier & Rice)
- Parexel International Corporation (Phoenix Parentco, Inc.)
- Almac Group
- Movianto (Walden Group SAS)
- Deutsche Post DHL Group (The Deutsche Post AG)
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Clinical Trial Supply & Logistics Market, by End-user
1.4.2 LAMEA Clinical Trial Supply & Logistics Market, by Therapeutic Area
1.4.3 LAMEA Clinical Trial Supply & Logistics Market, by Phase
1.4.4 LAMEA Clinical Trial Supply & Logistics Market, by Service
1.4.5 LAMEA Clinical Trial Supply & Logistics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Scenario and Composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Clinical Trial Supply & Logistics Market
Chapter 4. LAMEA Clinical Trial Supply & Logistics Market by End-user
4.1 LAMEA Pharmaceuticals Market by Country
4.2 LAMEA Biologicals Market by Country
4.3 LAMEA Medical Device Market by Country
Chapter 5. LAMEA Clinical Trial Supply & Logistics Market by Therapeutic Area
5.1 LAMEA Cardiovascular Diseases Market by Country
5.2 LAMEA Respiratory Diseases Market by Country
5.3 LAMEA CNS & Mental Disorders Market by Country
5.4 LAMEA Oncology Market by Country
5.5 LAMEA Others Market by Country
Chapter 6. LAMEA Clinical Trial Supply & Logistics Market by Phase
6.1 LAMEA Phase III Market by Country
6.2 LAMEA Phase II Market by Country
6.3 LAMEA Phase I Market by Country
6.4 LAMEA Phase IV Market by Country
Chapter 7. LAMEA Clinical Trial Supply & Logistics Market by Service
7.1 LAMEA Logistics & Distribution Market by Country
7.2 LAMEA Comparator Sourcing Market by Country
7.3 LAMEA Storage & Retention Market by Country
7.4 LAMEA Packaging, Labeling, & Blinding Market by Country
7.5 LAMEA Manufacturing Market by Country
7.6 LAMEA Others Market by Country
Chapter 8. LAMEA Clinical Trial Supply & Logistics Market by Country
8.1 Brazil Clinical Trial Supply & Logistics Market
8.1.1 Brazil Clinical Trial Supply & Logistics Market by End-user
8.1.2 Brazil Clinical Trial Supply & Logistics Market by Therapeutic Area
8.1.3 Brazil Clinical Trial Supply & Logistics Market by Phase
8.1.4 Brazil Clinical Trial Supply & Logistics Market by Service
8.2 Argentina Clinical Trial Supply & Logistics Market
8.2.1 Argentina Clinical Trial Supply & Logistics Market by End-user
8.2.2 Argentina Clinical Trial Supply & Logistics Market by Therapeutic Area
8.2.3 Argentina Clinical Trial Supply & Logistics Market by Phase
8.2.4 Argentina Clinical Trial Supply & Logistics Market by Service
8.3 UAE Clinical Trial Supply & Logistics Market
8.3.1 UAE Clinical Trial Supply & Logistics Market by End-user
8.3.2 UAE Clinical Trial Supply & Logistics Market by Therapeutic Area
8.3.3 UAE Clinical Trial Supply & Logistics Market by Phase
8.3.4 UAE Clinical Trial Supply & Logistics Market by Service
8.4 Saudi Arabia Clinical Trial Supply & Logistics Market
8.4.1 Saudi Arabia Clinical Trial Supply & Logistics Market by End-user
8.4.2 Saudi Arabia Clinical Trial Supply & Logistics Market by Therapeutic Area
8.4.3 Saudi Arabia Clinical Trial Supply & Logistics Market by Phase
8.4.4 Saudi Arabia Clinical Trial Supply & Logistics Market by Service
8.5 South Africa Clinical Trial Supply & Logistics Market
8.5.1 South Africa Clinical Trial Supply & Logistics Market by End-user
8.5.2 South Africa Clinical Trial Supply & Logistics Market by Therapeutic Area
8.5.3 South Africa Clinical Trial Supply & Logistics Market by Phase
8.5.4 South Africa Clinical Trial Supply & Logistics Market by Service
8.6 Nigeria Clinical Trial Supply & Logistics Market
8.6.1 Nigeria Clinical Trial Supply & Logistics Market by End-user
8.6.2 Nigeria Clinical Trial Supply & Logistics Market by Therapeutic Area
8.6.3 Nigeria Clinical Trial Supply & Logistics Market by Phase
8.6.4 Nigeria Clinical Trial Supply & Logistics Market by Service
8.7 Rest of LAMEA Clinical Trial Supply & Logistics Market
8.7.1 Rest of LAMEA Clinical Trial Supply & Logistics Market by End-user
8.7.2 Rest of LAMEA Clinical Trial Supply & Logistics Market by Therapeutic Area
8.7.3 Rest of LAMEA Clinical Trial Supply & Logistics Market by Phase
8.7.4 Rest of LAMEA Clinical Trial Supply & Logistics Market by Service
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc. (Pantheon)
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Product Launches and Product Expansions:
9.1.5.3 Acquisition and Mergers:
9.1.5.4 Geographical Expansions:
9.1.6 SWOT Analysis
9.2 Catalent, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional & Segmental Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Product Launches and Product Expansions:
9.2.5.2 Acquisition and Mergers:
9.2.5.3 Geographical Expansions:
9.3 Marken (United Parcel Service of America, Inc.)
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.4 Piramal Enterprises Limited
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Recent strategies and developments:
9.4.4.1 Product Launches and Product Expansions:
9.5 Deutsche Post DHL Group (The Deutsche Post AG)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Recent strategies and developments:
9.5.4.1 Acquisition and Mergers:
9.6 FedEx Corporation
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.7 Inizio Group Limited (Clayton, Dubilier & Rice)
9.7.1 Company Overview
9.8 Parexel International Corporation (Phoenix Parentco, Inc.)
9.8.1 Company Overview
9.9 Almac Group
9.9.1 Company Overview
9.10. Movianto (Walden Group SAS)
9.10.1 Company Overview
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Catalent, Inc.
- Marken (United Parcel Service of America, Inc.)
- Piramal Enterprises Limited
- FedEx Corporation
- Inizio Group Limited (Clayton, Dubilier & Rice)
- Parexel International Corporation (Phoenix Parentco, Inc.)
- Almac Group
- Movianto (Walden Group SAS)
- Deutsche Post DHL Group (The Deutsche Post AG)
Methodology
LOADING...
